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Abstract
Autoimmune diseases (AID) predominantly affect women of reproductive age. While basic molecular studies have
implicated persisting fetal cells in the mother in some AID, supportive epidemiological evidence is limited. We investigated
the effect of vaginal delivery, caesarean section (CS) and induced abortion on the risk of subsequent maternal AID. Using the
Danish Civil Registration System (CRS) we identified women who were born between 1960 and1992. We performed data
linkage between the CRS other Danish national registers to identify women who had a pregnancy and those who
developed AID. Women were categorised into 4 groups; nulligravida (control group), women who had 1st child by vaginal
delivery, whose 1st delivery was by CS and who had abortions. Log-linear Poisson regression with person-years was used for
data analysis adjusting for several potential confounders. There were 1,035,639 women aged .14 years and 25,570
developed AID: 43.4% nulligravida, 44.3% had their first pregnancy delivered vaginally, 7.6% CS and 4.1% abortions. The risk
of AID was significantly higher in the 1st year after vaginal delivery (RR=1.1[1.0, 1.2]) and CS (RR=1.3[1.1, 1.5]) but
significantly lower in the 1st year following abortion (RR=0.7[0.6, 0.9]). These results suggest an association between
pregnancy and the risk of subsequent maternal AID. Increased risks of AID after CS may be explained by amplified fetal cell
traffic at delivery, while decreased risks after abortion may be due to the transfer of more primitive fetal stem cells. The
increased risk of AID in the first year after delivery may also be related to greater testing during pregnancy.
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Introduction
Autoimmune diseases (AID) are most common among women
and increase in incidence following their reproductive years [1].
AID are caused by an immune reaction against self–antigens due
to disturbances in T or B cell regulation or function, and
autoimmunity may occur in a genetically susceptible individual if
an antigen is inadvertently targeted by T or B cells potentially due
to environmental or other factors triggering a break in tolerance
[2]. Those autoimmune diseases more common in women include
systemic lupus erythematosus (SLE; 9:1), autoimmune thyroid
disease (8:1), scleroderma (5:1), rheumatoid arthritis (4:1) and
multiple sclerosis (3:1), while type 1 diabetes and inflammatory
bowel diseases have almost the same female to male ratios of 1:1
and primary sclerosing cholangitis is more prevalent in men.
The human immune system shows some degree of sexual
dimorphism. In general, women have higher CD4 cell counts than
men, which contributes to an increased CD4/CD8 ratio [3],
higher levels of plasma IgM and greater Th1 cytokine production
[4]. Sex hormones have been implicated in autoimmunity due to
their capacity to modulate the immune response via androgen and
estrogen receptors [2]. Dramatic changes in the levels of estrogens,
progesterone and other hormones such as cortisol also occur
during pregnancy [1]. However, it is unlikely that the difference in
sex hormones between women and men alone explains the
preponderance of AID in women; most AID occur after
reproductive years and administration of sex steroids does not
have disease-altering effects [2].
Whether pregnancy or parity influence the development of AID
remains a subject of much debate [1,2]. Since pregnancy involves
complex interactions between hormonal and immunological
factors, it is plausible that it could have differing effects on the
development of AID [1]. While results of published studies on the
association between pregnancy and SLE are contradictory [5,6],
evidence suggests that the risk of multiple sclerosis onset is reduced
during gestation and increased in the first 6 months after
pregnancy [7,8]. It is unclear, despite much investigation, whether
there is an association between parity and the risk of rheumatoid
arthritis [9–11]. The currently available data do not provide
convincing evidence that parity provides an explanation for the
female predominance in the majority of autoimmune conditions.
Trafficking of fetal cells into the maternal circulation begins
very early in the pregnancy and the effects of this cell traffic are
long lasting [12,13]. All types of fetal cells, including stem cells,
cross the placenta during normal pregnancy to enter the maternal
blood and tissues, where they may be located decades after
pregnancy [14–16]. Fetal microchimerism is defined as low levels
of fetal cells persisting in maternal tissues during and after
pregnancy. The connection between fetal microchimerism and
human disease was first made by Nelson, who speculated that
microchimerism might be the underlying basis for the higher
prevalence of autoimmune disease in women [17]. This hypothesis
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(GVHD) to some autoimmune conditions, the prevalence of these
diseases in women, their increased incidence after reproductive
years, and the fact that GVHD increases with HLA incompati-
bility of the donor [18–20].
Fetal microchimerism has now been investigated in many
candidate AID, with some results supporting a role in disease
pathogenesis [16,20,21]. However, no direct association has been
shown between the presence of microchimeric cells and the
progression of AID. Reports now suggest that most autoimmune
conditions are not significantly associated with more microchi-
meric cells in blood or tissues when correctly compared to
controls. In addition, although fetal cells do appear to accumulate
in clinically affected organs, there is no conclusive evidence that
fetal cells cause autoimmune disease [20,22]. Some authors
suggest that an explanation for the conflicting results in studies
relating fetal microchimerism and autoimmune disease is the
migration of fetal cells preferentially into target organs of the
disease rather than the circulation. Other explanations for the
discrepancies in microchimerism results are differences in
experimental designs and the sensitivity and specificity of the
techniques used by different investigators [18]. Disease severity
might also be a factor, and it may be the tissue damage of AID that
leads to recruitment to and colonisation of injury sites by fetal cells,
rather than autoimmunity itself [16].
Factors predisposing to the development of fetal microchimer-
ism are much debated. There is more fetomaternal cell trafficking
where the placenta is abnormal and in certain complications of the
pregnancy such as fetal aneuploidy, pregnancy loss and pre-
eclampsia [20,23,24]. However, early fetal loss seems the only
pregnancy complication significantly influencing the development
of microchimerism, and it has been speculated that miscarriage
allows more primitive types of fetal cells with the greater capacity
to differentiate to enter the maternal circulation [25]. Fetoma-
ternal haemorrhage as a result of first trimester termination of
pregnancy has been shown to cause an 80-fold increase in the
number of fetal cells in maternal blood [26]. Fetomaternal
haemorrhage is also likely to be greater after operative when
compared to normal vaginal delivery and thus more microchimer-
ism should be established after caesarean section delivery. It is
accepted that even short-term microchimerism can lead to
autoimmune disease and the higher amount of trafficking at
caesarean section might increase the exposure of these mothers
and facilitate the development of autoimmune disease.
The objective of this study was to find out whether risk of new
onset autoimmune disease is higher after delivery by caesarean
section compared to vaginal delivery and we also aimed to
quantify the risk of autoimmune disease after abortion. We
investigated the effect of vaginal delivery, caesarean section (CS)
and abortion on the risk of subsequent maternal AID using data
from the Danish National Registers.
Methods
Study cohort
The study cohort consisted of all women born in Denmark
between January 1, 1962 and December 31, 1992. The data were
obtained by linking the Danish Civil Registration System [27], the
Danish National Hospital Register [28] and the Danish Medical
Birth Register [29]. The linkage process was performed using the
unique personal identification number (CPR-number), which is
used in all national registers and enables accurate linkage between
all registers [27]. The linkage process enabled us to identify the
firstborn children for those women with children, mother and
infant place of birth, date of delivery, infant sex, date of migration
of any woman who left the country and the woman’s date of death
if the woman died. From the Medical Birth Register, we obtained
data on mode of delivery, induced abortion and date of abortion,
single or multiple gestations. From the National Hospital Register
we obtained information on AID diagnoses, together with
inpatient or outpatient hospital contact. The National Hospital
Register includes details of inpatient hospitalization from 1977 and
inpatient and outpatient contact from 1995 onward. Date of onset
of AID was defined as the date of the first contact with the hospital
that led to the diagnosis.
Methods
Women were grouped in four exposure categories based on
their first pregnancy only: 1) Women who had no previous
pregnancy; 2) women who had a vaginal delivery; 3) women who
had a CS, and 4) women who had an abortion. Abortion was
defined as induced abortion before 20 weeks gestation based on
International Classification of Disease revisions 8 and 10 (ICD-8:
640, 641, 642 & ICD-10: DO04) [30,31]. Thirty AID were
identified according to ICD-8 and ICD-10 and are listed in
Table 1. More details on AID in Denmark are available from
recent publications [32].
The AID follow-up period was divided into 1) during pregnancy
(this category was included for completeness), 2) first year following
pregnancy, 3) second year following delivery, 4) third year
following delivery, 5) more than three years but less than 10
years following delivery and 6) 10 years or more. This was also
applied to the follow-up period following abortion. The follow-up
period started in January 1, 1994 and ended in December 31,
2006. Women were followed-up for AID from their 14th birthday
until their deaths, migration, onset of AID or end of study period,
whichever came first. Women with a diagnosis of AID that
included diabetes before the start of the follow-up period were
excluded from the study cohort; as diabetes is generally accepted
to have a different aetiology than other AID and its onset usually
precedes the childbearing years.
Statistical analysis
Log-linear Poisson regression with aggregated person-years data
was used to estimate the relative risk of AID in relation to vaginal
delivery, CS and abortions [33]. The models of AID in relation to
vaginal delivery and CS were adjusted for age (14–15, 16–17, and
in 2 years categories thereafter), calendar year (94–95, 96–97, 98–
99, 2000–2001, 2002–2003, 2004–2005, 2006), infant sex (male,
female, multiple gestation, no pregnancy) and place of birth
(capital city, capital city suburbs, large city, small city, rural area).
Models of AID in relation to abortion were adjusted for age,
calendar year and place of birth since we had no information on
fetal sex in abortions. Age and calendar year were generated as
time dependent variables and the other variables were time fixed.
The Poisson models were run separately for vaginal delivery, CS
and abortion. The reference group in all the models consisted of
women who had no records of pregnancy including abortion.
Sensitivity analyses were performed to examine whether age,
infant sex or multiple gestation had an effect on association
between risk of AID and mode of delivery.
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Danish Data Protection Agency and the Danish National Board of
Health. The study was based on secondary data and no individuals
were approached, nor did we have access to any other information
from the participants. Thus it was not necessary to seek written
consent.
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During the study period there were 1,035,639 women in
Denmark aged 14 years or more. Of those women 25,570 (2.4%)
had a diagnosis of AID during 10,786,229 person-years of follow-
up. 459,049 women had their first pregnancy delivered vaginally
and 11,439 (2.5%) had an AID. 78,694 women had their first
pregnancy delivered by CS, of which 1,787 (2.3%) had an AID,
and 186,220 had an abortion in their first pregnancy, of which
4,723 (2.5%) had an AID. 455,214 women had no record of a
pregnancy during the study period, of which 11,165 (2.4%) had an
AID diagnosis. Of the 186,220 women who had abortions, only
42,682 had no records of other pregnancies, thus the numbers do
not add up to 1,035,639. When we excluded women who had
records of childbirth and abortions in the study cohort, we had
334,205 women with a normal delivery and 60,000 delivered by
CS, while 42,682 had abortions, 455,214 had no pregnancy, and
143,538 had abortions and delivery.
Table 2 presents the incidence of AID in relation to age,
calendar year, infant sex, multiple gestation and place of birth. It
appears that women who were pregnant had a higher incidence
of AID than those who had no pregnancy records and women
who had singletons had slightly higher incidence of AID than
those who had multiple gestation. It also appeared that the
incidence of AID increased with age and with the size of the place
of birth.
Table 3 presents the relative risk (RR) estimates of AID in
relation to normal delivery, CS and abortion. There was no
evidence to support an association between risk of AID and
vaginal delivery (RR=0.91, [95% CI: 0.84, 0.99]), CS
(RR=1.02, [95% CI: 0.94, 1.11]) or abortion (RR=0.97, [95%
CI: 0.92, 1.04]) for all follow-up period after delivery. The
estimates show that the risk of AID during pregnancy was
significantly reduced in relation to vaginal delivery (RR=0.76,
[95% CI: 0.63, 0.93]) and significantly increased in relation to CS
(RR=1.82, [95% CI: 1.39, 2.38]). In contrast, the RR of AID
during pregnancy in relation to abortion was close to one and not
significantly changed (RR=0.92, [95% CI: 0.62, 1.37]).
The risk of AID appeared to be moderately increased in the first
year following a pregnancy that ended in vaginal delivery
Table 1. International classification of disease: autoimmune disease.
Autoimmune Disease Categorization Prevalence per 1000
ICD8 ICD10 ICD8/ICD10 ICD10 ONLY
Pernicious Anemia 281.0 D51.0 0.54 0.42
Autoimmune Hemolytic Anemia 283.90–91 D59.1 0.14 0.12
Idiopathic Thrombocytopenic Purpura 446.49 D69.3 0.49 0.48
Thyrotoxicosis 242.00 E05.0 4.99 4.82
Autoimmune Thyroiditis 245.03 E06.3 0.63 0.57
Type 1 Diabetes 249 E10 9.75 9.58
Primary Adrenocortical Insufficiency 255.1 E27.1 0.23 0.20
Multiple Sclerosis 340 G35 2.17 2.04
Guillain Barre Syndrome 354 G61.0 0.60 0.27
Iridocyclitis 364 H20 2.17 1.94
Crohn’s Disease 563.01 K50 2.78 2.63
Ulcerative Colitis 563.19 K51 5.65 5.25
Autoimmune Hepatitis 571.93 K73 0.51 0.39
Primary Biliary Cirrhosis 571.90 K74.3 0.16 0.13
Coeliac Disease 269.00 K90.0 0.76 0.70
Pemphigus 694 (6694.05) L10 0.08 0.07
Pemphigoid 694.05 L12 0.14 0.14
Psoriasis vulgaris 696.09–10, 696.19 L40 (xL40.4) 3.43 2.94
Alopecia Areata 704.00 L63 0.34 0.30
Vitiligo 709.01 L80.9 0.24 0.21
Seropositive Rheumatoid Arthritis 712.19, 712.39, 712.59 M05–M06 6.20 5.82
Juvenile Arthritis 712.09 M08 0.86 0.71
Wegener’s Granulomatosis 446.29 M31.3 0.18 0.18
Dermatopolymyositis 716 M33 0.21 0.17
Polymyalgia Rheumatica 446.30–31, 446.39 M31.5–6, M35.3 3.02 2.78
Myasthenia Gravis 733.09 G70.0 0.22 0.19
Systemic Sclerosis 734.0 M34 0.30 0.28
Systemic Lupus Erythematosus 734.19 M32.1, M32.9 0.59 0.53
Sjogren’s Syndrome 734.90 M35.0 0.78 0.75
Ankylosing Spondylitis 712.49 M45.9 0.85 0.75
doi:10.1371/journal.pone.0019658.t001
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1.10, 1.55]) and moderately reduced in the first year following
abortion (RR=0.70, [95% CI: 0.56, 0.88]). However, the risk of
AID was not significantly changed after the first year following
delivery apart from a reduction of the risk between year three and
year 10 following normal delivery (Table 3).
Table 2. Distribution of 25,570 women with autoimmune disease and 10.8 million person-years of follow-up in a cohort of 1
million women residing in Denmark.
Variable Cases Person years Incidence per 100,000 person years
Infant Sex
Female 6289 2300317 273.2
Male 6572 2423568 271.2
Multiple gestation 185 72368 255.6
No children 12524 5989845 209.1
Age
14–19 3007 2100277 143.2
20–25 5021 2295805 218.7
26–29 4377 1694776 258.3
30–35 7188 2612313 275.2
36–41 4816 1669130 288.5
42+ 1161 413795.5 280.6
Calendar year
94–95 2941 1413014 208.1
96–97 3258 1502817 216.8
98–99 3723 1588335 234.4
2000–2001 4111 1676766 245.2
2002–2003 4654 1768593 263.1
2004–2005 4760 1866601 255.0
2006 2123 969972 218.9
Place of birth (mother)
Capital city 4585 1728824 265.2
Capital city suburbs 2553 1084167 235.5
Large city 3500 1399005 250.2
Small city 9156 3871445 236.5
Rural area 5776 2702656 213.7
a ‘No children’ includes abortions.
doi:10.1371/journal.pone.0019658.t002
Table 3. Adjusted relative risk estimates of maternal autoimmune disease in relation to pregnancy.
Follow-up period
AID and vaginal
delivery (N)
Vaginal delivery
adjusted RR
(95% CI
AID and
CS (N)
CS Adjusted
RR (95% CI)
AID and
abortions (N)
Abortion Adjusted
RR (95% CI)
No pregnancy 11165 Reference 11165 Reference 11165 Reference
During first pregnancy 105 0.76(0.63, 0.93) 54 1.82(1.39, 2.38) 25 0.92(0.62, 1.37)
All follow-up period 8206 0.91(0.84, 0.99) 1317 1.02(0.94, 1.11) 1154 0.97(0.92, 1.04)
0 to 11 months 673 1.15(1.03, 1.28) 155 1.30(1.10, 1.55) 78 0.70(0.56, 0.88)
12 to 23 539 0.91(0.81, 1.02) 111 0.99(0.81, 1.20) 104 0.96(0.79, 1.16)
24 to 35 544 0.90(0.81, 1.01) 114 1.08(0.89, 1.31) 93 0.90(0.74, 1.11)
36 to 119 3425 0.84(0.78, 0.92) 546 0.97(0.87, 1.07) 566 1.02(0.94, 1.11
120+ 3025 0.95(0.88, 1.04) 391 1.01(0.89, 1.13) 313 1.02(0.91, 1.15)
Vaginal delivery and CS models were adjusted for age, calendar year, infant sex and place of birth. Abortion models were adjusted for age, calendar year and infant
place of birth. We had no information about fetal sex or number of babies in abortions. Repeating vaginal delivery and CS models for singletons only did not change the
estimates. Negative binomial regression models showed that the Poisson models were not over dispersed.
doi:10.1371/journal.pone.0019658.t003
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repeated the Poisson models as described earlier for three age
groups: 1) ,24 years; 2) $24 and ,35 years; 3) $35 years. The
RR estimates of AID were similar in the three age groups
following vaginal delivery and abortion. In contrast, the RR of
AID in the first year following CS appeared to be higher in the
younger (RR=1.62; [95% CI: 1.03, 2.57]) and older women
(RR=1.61, [95% CI: 0.97, 2.68]). Also, there was a non-
significant increase in risk of AID in the second year following CS
in the older women (RR=1.42, [95% CI: 0.87, 2.33]).
We also examined the effect of fetal sex and multiple gestations
on the observed estimates. Separate analyses for males, females
and singleton pregnancies did not change the results materially.
Tables 4, 5, 6, 7 present the relative risk estimates of specific
AID types in relation to vaginal delivery, CS and abortion. There
was little evidence to support an association between risk of
rheumatoid arthritis (RA) and vaginal delivery (RR=0.72, [95%
CI: 0.55, 0.96]), CS (RR=1.17, [95% CI: 0.88, 1.55]) or abortion
(RR=0.93, [95% CI: 0.74, 1.18]) during the follow-up period
after delivery. A reduction of the risk of RA three to 10 years after
vaginal delivery was observed (Table 4). No association was
observed between the mode of delivery and Multiple Sclerosis
(Table 5). The risk of thyrotoxicosis was increased in the first year
after both vaginal delivery (RR 2.15, [95% CI: 172, 2.68]) and CS
(RR 1.87, [85% CI: 1.33, 2.64]), but not when the first pregnancy
resulted in an abortion (Table 6). Finally the risk of inflammatory
bowel disease appeared to be reduced following abortion
(RR=0.86, [95% CI: 0.76, 0.97]), but was not significantly
changed after vaginal delivery or CS in the same follow up period
(Table 7).
Discussion
In this study we report the risk of autoimmune disease during
and after pregnancy. Overall the risk of AID in women was
significantly higher in the first year following vaginal delivery or
CS, but was lower in the first year following abortion. While the
risk of AID was reduced between the 3rd and 10th year following
vaginal delivery, there was no evidence of a change in the risk of
AID beyond the first year following CS or abortion. However,
women who were pregnant had a higher incidence of AID than
those who had no pregnancy records.
Pregnancy has both short and long term effects on the woman’s
immune system [2]. Fetal microchimerism, or low levels of fetal
cells persisting in the mother, is implicated in the pathogenesis of
autoimmune diseases, which have a predilection for women after
childbearing [18]. While basic molecular studies have implicated
persisting fetal cells in the mother in some AID, supportive
Table 4. Adjusted relative risk estimates of maternal Seropositive Rheumatoid Arthritis in relation to pregnancy.
Follow-up period
Cases in
vaginal
delivery
Vaginal delivery
adjusted RR
(95% CI)
Cases
in CS
CS Adjusted
RR (95% CI)
Cases in
abortions
Abortion Adjusted
RR (95% CI)
No pregnancy (reference) 721 Reference 721 Reference 721 Reference
During pregnancy 6 0.64(0.28 1.43) 1 0.49(0.07, 3.46) 1 0.57(0.09, 4.08)
All follow-up period 758 0.72(0.55, 0.96) 143 1.17(0.88, 1.55) 79 0.93(0.74, 1.18)
0 to 11 months 50 0.82(0.55, 1.21) 10 1.01(0.58, 1.95) 2 0.28(0.07, 1.12)
12 to 23 26 0.41(0.26, 0.67) 12 1.25(0.68, 2.32) 7 0.99(0.47, 2.09)
24 to 35 45 0.70(0.47, 1.05) 10 1.09(0.56, 2.12) 4 0.60(0.22, 1.59)
36 to 119 293 0.64(0.48, 0.87) 59 1.12(0.79, 1.59) 37 0.97(0.69, 1.35)
120+ 344 0.86(0.64, 1.16) 52 1.26(0.88, 1.81) 29 1.16(0.79, 1.70)
Vaginal delivery and CS models were adjusted for age, calendar year, infant sex and place of birth. Abortion models were adjusted for age, calendar year, infant place of
birth. We had no information about fetal sex or number of babies in abortions.
doi:10.1371/journal.pone.0019658.t004
Table 5. Adjusted relative risk estimates of maternal Multiple Sclerosis in relation to pregnancy.
Follow-up period
Cases in
vaginal
delivery
Vaginal delivery
adjusted RR (95% CI)
Cases
in CS
CS Adjusted
RR (95% CI)
Cases
in abortion
Abortion Adjusted
RR (95% CI)
No pregnancy (reference) 865 Reference 865 Reference 865 Reference
During pregnancy 8 0.58(0.29, 1.17) 4 1.31(0.49, 3.50) 3 1.51(0.48, 4.68)
All follow-up period 756 1.06(0.82, 1.38) 109 0.93(0.71, 1.22) 118 0.99(0.81, 1.20)
0 to 11 months 47 1.14(0.78, 1.68) 12 1.26(0.69, 2.29) 8 0.94(0.47, 1.88)
12 to 23 25 0.58(0.36, 0.93) 7 0.75(0.35, 1.63) 9 1.01(0.52, 1.95)
24 to 35 46 1.03(0.70, 1.52) 5 0.56(0.23, 1.38) 8 0.90(0.45, 1.81)
36 to 119 333 1.03(0.78, 1.36) 51 0.99(0.71, 1.40) 52 0.94(0.71, 1.24)
120+ 305 1.18(0.89, 1.57) 34 0.89(0.60, 1.32) 41 1.08(0.79, 1.50)
Vaginal delivery and CS models were adjusted for age, calendar year, infant sex and place of birth. Abortion models were adjusted for age, calendar year, infant place of
birth. We had no information about fetal sex or number of babies in abortions.
doi:10.1371/journal.pone.0019658.t005
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first epidemiological study on the risk of AID following pregnancy.
The main strength of the paper is the large cohort used and the
fact that it is population based, which avoids the problem of
selection bias.
We hypothesized that the risk of AID is increased following
pregnancy. Further, if fetomaternal cell trafficking is implicated in
the etiology of AID after pregnancy, we expected the highest
increase in AID diagnosis following (i) CS, due to increased
fetomaternal hemorrhage, and (ii) abortion, as fetal loss has been
shown to be the only pregnancy complication significantly
influencing microchimerism. The first year after pregnancy should
be relevant, being the time period closest to the fetomaternal
hemorrhage occurring at delivery. Our results confirm an increase
in AID in the first year after CS. The unexpected finding of a
reduction in AID risk after abortion may be explained by the
premise that early fetal loss allows a higher number of fetal stem or
progenitor cells to enter maternal blood, and that these cell types
are more likely to engraft maternal tissues long-term, and be
beneficial in their role [13,20,25].
As pregnancy involves complicated and dynamic interactions
between the endocrine and immune systems, it is possible that it
could have differential effects on the development of an autoim-
mune disease depending on its timing or even complexity relative to
the events that are likely to precede obvious clinical disease [1]. This
may explain our findings during and following pregnancy, and the
variation between mode of delivery or length of pregnancy.
There were several limitations to our approach. First, since we
included data on the first pregnancy only, we did not account for
the effect of subsequent pregnancies on the risk of AID. However,
the effect we observed on risk of AID was manifest in the first year
after pregnancy, which precludes subsequent pregnancies being
responsible in the vast majority of women. We accept that in some
cases another pregnancy may have occurred in the year follow-up
period after a first trimester abortion and that this instead may
influence the reduction in AID found. Other studies have
previously failed to show an association with parity and the
development of AID [1].
Second, it is possible that the increased risk of AID that we
observed is linked to the increased risk of AID presenting during
pregnancy. Women may be more likely to be tested for AID (along
with other diseases) during pregnancy, and it is also possible that
some of these diagnoses were not confirmed until after pregnancy.
Further, women with symptoms related to AID may experience a
complicated pregnancy and thus require delivery by CS. If that is
the case then the association that we describe could be related to
more testing during pregnancy rather than effects of fetomaternal
cell trafficking.
Table 6. Adjusted relative risk estimates of maternal Thyrotoxicosis in relation to pregnancy.
Follow-up period
Cases
in vaginal
delivery
Vaginal
delivery adjusted
RR (95% CI) Cases in CS
CS Adjusted
RR (95% CI)
Cases
in abortions
Abortion Adjusted
RR (95% CI)
No pregnancy (reference) 1545 Reference 1545 Reference 1545 Reference
During pregnancy 27 1.17(0.80, 1.72) 11 2.14(1.18, 3.88) 3 0.86(0.28, 2.67)
All follow-up period 1843 1.18(0.99, 1.41) 278 1.18(0.99, 1.42) 226 1.19(1.03, 1.37)
0 to 11 months 204 2.15(1.72, 2.68) 40 1.87(1.33, 2.64) 11 0.75(0.41, 1.35)
12 to 23 149 1.51(1.19, 1.92) 27 1.33(0.89, 1.98) 15 0.99(0.60, 1.65)
24 to 35 121 1.19(0.93, 1.53) 20 1.04(0.66, 1.65) 21 1.40(0.91, 2.17)
36 to 119 721 1.01(0.83, 1.21) 107 1.04(0.82, 1.31) 113 1.23(1.02, 1.49)
120+ 648 1.14(0.94, 1.39) 84 1.19(0.92, 1.54) 66 1.23(0.95, 1.58)
Vaginal delivery and CS models were adjusted for age, calendar year, infant sex and place of birth. Abortion models were adjusted for age, calendar year, infant place of
birth. We had no information about fetal sex or number of babies in abortions.
doi:10.1371/journal.pone.0019658.t006
Table 7. Adjusted relative risk estimates of maternal IBD (Colitis and Crohn’s disease) in relation to pregnancy.
Follow-up period
Cases in
normal
delivery
Normal delivery
RR (95% CI) Cases in CS
CS Adjusted
RR (95% CI)
Cases in
abortions
Abortion Adjusted
RR (95% CI)
No pregnancy (reference) 3442 Reference 3442 Reference 3442 Reference
During pregnancy 26 0.68(0.46, 1.00) 17 2.16(1.34, 3.49) 5 0.56(0.23, 1.35)
All follow-up period 1823 0.91(0.77, 1.07) 263 0.85(0.71, 1.01) 279 0.86(0.76, 0.97)
0 to 11 months 167 1.02(0.82, 1.27) 33 0.98(0.68, 1.41) 16 0.44(0.27, 0.72)
12 to 23 144 0.90(0.71, 1.13) 27 0.87(0.59, 1.30) 26 0.74(0.50, 1.09)
24 to 35 129 0.83(0.65, 1.05) 30 1.06(0.73, 1.55) 31 0.95(0.67, 1.36)
36 to 119 802 0.86(0.72, 1.03) 109 0.79(0.63, 0.99) 156 1.00(0.85, 1.18)
120+ 581 0.97(0.81, 1.17) 64 0.81(0.61, 1.07) 50 0.78(0.58, 1.03)
Vaginal delivery and CS models were adjusted for age, calendar year, infant sex and place of birth. Abortion models were adjusted for age, calendar year, infant place of
birth. We had no information about fetal sex or number of babies in abortions.
doi:10.1371/journal.pone.0019658.t007
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the risk of AID after spontaneous abortion. This would be relevant
as not only are the risks of spontaneous abortion increased with
some AID, but also microchimerism is more likely to be
established after induced abortion. We were only able to obtain
data on induced abortion from the Danish Medical Birth Register.
Finally, we report limited details on the increased risk of each
individual AID, as small numbers of affected women in some
disease categories during the follow-up period prevents accurate
statistical analysis in all groups. Nonetheless we believe these data
are important to report, as they show the relationship between
pregnancy and maternal AID in a large population-based cohort
over a detailed follow-up period.
We suggest an association between pregnancy and the risk of
subsequent maternal AID, with a significant impact on the first
year after delivery. However, given the number of unanswered
questions and the available data, conclusions on the role of fetal
microchimerism in the development of autoimmune diseases
cannot be drawn.
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